ArticleJournal of virology2026
The newly developed porcine-origin parainfluenza virus PIV5-JS17 serves as an exogenous gene delivery system for swine.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging and re-emerging swine viral infectious diseases impose substantial economic burdens. Additionally, swine, which frequently interact with humans, may facilitate virus evolution, posing a risk to public health security. Consequently, there is a pressing need to develop safe, effective, and rapid vaccine platforms, with vector vaccine being a viable option. In this study, we utilized the enhanced green fluorescent protein (eGFP) as an exogenous reporter to investigate the intergenic regions of the PIV5-JS17 strain for expressing exogenous proteins. These regions included N-P, P-M, M-F, F-SH, SH-HN, and HN-L. Our findings revealed that exogenous gene expression varied at different positions, with the expression cassette containing the non-coding sequence within the P-M intergenic region achieving the highest eGFP fluorescence intensity. Then, we successfully established a porcine infection model through oral administration of the recombinant virus, identified the target organs infected, and verified the safety of the viral vector in swine. Furthermore, using porcine deltacoronavirus (PDCoV)-S protein as a model antigen, it was demonstrated that the recombinant virus triggered a robust humoral and cellular immune responses. In conclusion, we have developed a novel oral gene delivery system for swine, providing insights and guidance for the design of vector vaccines based on the newly discovered porcine PIV5, the selection of appropriate exogenous gene insertion sites, and vaccine delivery strategies.IMPORTANCEThe research presented in this paper hinges on the fortunate isolation of the PIV5-JS17 strain from the intestines of pigs. Given the pressing demand for oral vaccines, the emergence of this novel PIV5 strain capable of infecting both the respiratory and intestinal tracts has sparked our interest in developing it as a vector vaccine. Utilizing eGFP as a model exogenous gene, our findings reveal that the P/M intergenic region serves as the optimal site for the insertion of exogenous genes. Using the PDCoV-S protein as a model antigen, the study shows that this novel porcine-derived PIV5 virus vector presents innovative prevention methods and gene delivery strategies for addressing porcine infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.